RaQualia Pharma Third Quarter 2024 Earnings: JP¥0.74 loss per share (vs JP¥6.57 loss in 3Q 2023)
RaQualia Pharma (TSE:4579) Third Quarter 2024 Results
Key Financial Results
- Revenue: JP¥958.4m (up 99% from 3Q 2023).
- Net loss: JP¥16.0m (loss narrowed by 89% from 3Q 2023).
- JP¥0.74 loss per share (improved from JP¥6.57 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
RaQualia Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with RaQualia Pharma.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4579
RaQualia Pharma
Engages in the research and development of pharmaceutical compounds worldwide.
Reasonable growth potential with mediocre balance sheet.
